Hepatitis C virus reinfection following treatment among people who use drugs

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Grady, Bart P ^a,c   Schinkel, Janke ^b   Thomas, Xiomara V ^b   Dalgard, Olav ^c  

^a Department of Infectious Diseases   (Norway)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Clearance; Hepatitis C virus; Mixed infection; Sequence analysis; Substance abuse

Indexed keywords

HEPATITIS C VACCINE; PEGINTERFERON; RIBAVIRIN;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL DECISION MAKING; DRUG USE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; PEOPLE WHO INJECT DRUG; PERSISTENT INFECTION; PRIMARY INFECTION; PRIORITY JOURNAL; REINFECTION; VIRAL CLEARANCE;

CLEARANCE; HEPATITIS C VIRUS; MIXED INFECTION; SEQUENCE ANALYSIS; SUBSTANCE ABUSE;

HEPATITIS C; HUMANS; INCIDENCE; RECURRENCE; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84880980236     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit301     Document Type: Article

References (39)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
3. Grebely J, Matthews GV, Hellard M, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011; 55: 76-85.
4. Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23: 23-31.
5. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-73.
6. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36(5 suppl 1):S210-9.
7. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93: 141-7.
8. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39: 1540-3.
9. Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J Gastroenterol Hepatol 2010; 25: 1276-80.
10. Currie SL, Ryan JC, Tracy D, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 2008; 93: 148-54.
11. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8: 45-9.
12. Grady BPX, Vanhommerig JW, Schinkel J, et al. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur J Gastroenterol Hepatol 2012; 24: 1302-7.
13. Grebely J, Knight E, Ngai T, et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 2010; 25: 1281-4.
14. Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2012; 55: 1058-69.
15. Lambers FA, Prins M, Thomas X, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011; 25:F21-7.
16. Asselah T, Vidaud D, Doloy A, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 2003; 52: 900-2.
17. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57(Suppl 2):S80-9.
18. Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 12: 408-14.
19. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-8.
20. Lum PJ, Sears C, Guydish J. Injection risk behavior among women syringe exchangers in San Francisco. Subst Use Misuse 2005; 40: 1681-96.
21. Golub ET, Strathdee SA, Bailey SL, et al. Distributive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend 2007; 91(suppl 1):S30-8.
22. Blackard JT, Sherman KE. Hepatitis C virus coinfection and superinfection. J Infect Dis 2007; 195: 519-24.
23. Arends JE, van Assen S, Stek CJ, et al. Pegylated interferon-alpha monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C. Antivir Ther 2011; 16: 979-88.
24. van de Laar TJ, Molenkamp R, van den Berg C, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 2009; 51: 667-74.
25. Pham ST, Bull RA, Bennett JM, et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 2010; 52: 1564-72.
26. Osburn WO, Fisher BE, Dowd KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315-24.
27. de Bruijne J, Sullivan JC, Kieffer TL, et al. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment. J Clin Virol 2012; 53: 174-7.
28. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol 2007; 45: 1102-12.
29. Corbet S, Bukh J, Heinsen A, Fomsgaard A. Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. J Clin Microbiol 2003; 41: 1091-100.
30. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, TyndallMW. Hepatitis C virus reinfection in injection drug users. Hepatology 2006; 44: 1139-45.
31. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-83.
32. Micallef JM, Macdonald V, Jauncey M, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007; 14: 413-8.
33. Aitken CK, Lewis J, Tracy SL, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008; 48: 1746-52.
34. Page K, Osburn W, Evans J, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis 2013; 56: 405-13.
35. Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012; 209: 61-75.
36. Abdel-Hakeem MS, Bedard N, Badr G, et al. Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J Virol 2010; 84: 10429-35.
37. Missale G, Pilli M, Zerbini A, et al. Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut 2012; 61: 1076-84.
38. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139:1586-92, 92 e1.
39. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200: 1216-26.